Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Common Equity (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Common Equity data on record, last reported at $468.8 million in Q3 2023.

  • For Q3 2023, Common Equity fell 20.01% year-over-year to $468.8 million; the TTM value through Sep 2023 reached $468.8 million, down 20.01%, while the annual FY2022 figure was $535.0 million, 25.78% up from the prior year.
  • Common Equity reached $468.8 million in Q3 2023 per CGEM's latest filing, down from $499.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $604.6 million in Q2 2022 and bottomed at $87.6 million in Q3 2020.
  • Average Common Equity over 4 years is $392.8 million, with a median of $458.5 million recorded in 2021.
  • Peak YoY movement for Common Equity: soared 408.25% in 2021, then decreased 20.01% in 2023.
  • A 4-year view of Common Equity shows it stood at $200.3 million in 2020, then skyrocketed by 112.35% to $425.4 million in 2021, then grew by 25.78% to $535.0 million in 2022, then dropped by 12.38% to $468.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Common Equity were $468.8 million in Q3 2023, $499.6 million in Q2 2023, and $485.6 million in Q1 2023.